- Home
- ORIC vs TNDM Comparison
ORIC vs TNDM Comparison
Compare ORIC & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- TNDM
- Stock Information
- Founded
- ORIC 2014
- TNDM 2006
- Country
- ORIC United States
- TNDM United States
- Employees
- ORIC N/A
- TNDM N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- TNDM Medical/Dental Instruments
- Sector
- ORIC Health Care
- TNDM Health Care
- Exchange
- ORIC Nasdaq
- TNDM Nasdaq
- Market Cap
- ORIC 1.1B
- TNDM 1.1B
- IPO Year
- ORIC 2020
- TNDM 2013
- Fundamental
- Price
- ORIC $12.20
- TNDM $18.41
- Analyst Decision
- ORIC Strong Buy
- TNDM Buy
- Analyst Count
- ORIC 8
- TNDM 16
- Target Price
- ORIC $17.86
- TNDM $21.63
- AVG Volume (30 Days)
- ORIC 1.1M
- TNDM 2.2M
- Earning Date
- ORIC 11-13-2025
- TNDM 11-06-2025
- Dividend Yield
- ORIC N/A
- TNDM N/A
- EPS Growth
- ORIC N/A
- TNDM N/A
- EPS
- ORIC N/A
- TNDM N/A
- Revenue
- ORIC N/A
- TNDM $1,007,001,000.00
- Revenue This Year
- ORIC N/A
- TNDM $8.27
- Revenue Next Year
- ORIC N/A
- TNDM $9.63
- P/E Ratio
- ORIC N/A
- TNDM N/A
- Revenue Growth
- ORIC N/A
- TNDM 17.87
- 52 Week Low
- ORIC $3.90
- TNDM $9.98
- 52 Week High
- ORIC $14.93
- TNDM $38.28
- Technical
- Relative Strength Index (RSI)
- ORIC 46.07
- TNDM 67.25
- Support Level
- ORIC $12.02
- TNDM $13.24
- Resistance Level
- ORIC $13.04
- TNDM $18.64
- Average True Range (ATR)
- ORIC 0.75
- TNDM 1.13
- MACD
- ORIC -0.12
- TNDM 0.33
- Stochastic Oscillator
- ORIC 20.69
- TNDM 96.02
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.